Pfizer (PFE) Stock Forecast 2026–2030: Long-Term Outlook
Examine the Pfizer (PFE) stock forecast through 2030. We analyze recent earnings, Wall Street targets, and long-term revenue scenarios for PFE stock.

On this page
Pfizer, Inc. (PFE) trades around $29.39 per share as of November 6, 2026, giving the drugmaker a market value of roughly $167.5 billion. If you own Pfizer in your brokerage account or dividend portfolio, you are holding a legacy pharmaceutical giant managing post-pandemic product demand and shifting commercial revenues.
Long-range stock forecasts are not reliable predictions or guarantees. Over a five-year horizon, drug trial results, patent cliffs, and regulatory approvals alter commercial outcomes. The scenario analysis below lays out reasonable paths for Pfizer’s stock through 2030 based on revenue growth and valuation multiples.
| Share price | $29.39 (Nov 6, 2026) |
| Market value | about $167.5 billion |
| 52-week range | $23.62 – $31.44 |
| Revenue, last 12 months | about $63.6 billion |
| Revenue growth, last fiscal year | -2% |
| Net income, last 12 months | about $4.1 billion |
| Price-to-sales | about 2.6× |
| Price-to-earnings | about 41× |
| Analyst 12-month target | average $30.28 (range $25 – $36); 6 buy, 14 hold, 1 sell |
Market data from Nasdaq as of November 8, 2026. Check current figures before making any decision.
What changed since our last update
Since our October 28, 2026 update, Pfizer’s share price edged up 0.4% from $29.28 to $29.39. Wall Street’s consensus 12-month average price target nudged higher from $29.62 to $30.28, reflecting recent third-quarter earnings outperformance.
Our 2030 model scenarios shifted slightly to account for the higher base stock price: the bull-case implied target rose from $43.95 to $44.12, the base-case estimate rose from $32.95 to $33.08, and the bear-case price moved from $21.62 to $21.70.
What Pfizer does: products and revenues
Pfizer is a premier innovative biopharmaceutical company with over 175 years of commercial history. The company applies global clinical resources to discover, develop, manufacture, and market prescription medicines and vaccines across developed and emerging markets.
Its core revenue comes from selling treatments directly to health care providers, governments, wholesalers, and pharmacy distributors. Pfizer’s commercial pipeline targets oncology, rare diseases, immunology, vaccines, and metabolic conditions.
Where the business stands: revenue and profit trends
Pfizer generated $63.6 billion in revenue over the last four reported quarters, maintaining a steady baseline after multi-year fluctuations in demand for pandemic vaccines and therapies. For the full fiscal year ending December 31, 2025, Pfizer pulled in $62.6 billion in revenue, down 1.6% from $63.6 billion in fiscal year 2024. Fiscal year 2023 revenue stood at $59.6 billion.
Recent quarterly results show positive momentum against lower expectations. For the quarter ending September 27, 2026, Pfizer reported revenue of $16.58 billion and earnings per share of $0.87, topping the consensus estimate of $0.72 by 20.83%. In the quarter ending June 28, 2026, revenue hit $15.03 billion with EPS of $0.77 (a 13.24% surprise above the $0.68 consensus).
The quarter ending March 29, 2026 recorded $14.45 billion in revenue and $0.75 EPS (a 5.63% beat), while the quarter ending December 31, 2025 delivered $17.56 billion in revenue and $0.66 EPS (a 15.79% surprise). Over the trailing twelve months, net income totalled $4.1 billion, compared to $7.8 billion in fiscal year 2025 and $8.1 billion in 2024.
Pfizer Quarterly Revenue (Trailing 4 Quarters)
Q4 2025: $17.56B
Q1 2026: $14.45B
Q2 2026: $15.03B
Q3 2026: $16.58B
Total LTM Revenue: $63.6B
Pfizer trades at a price-to-sales ratio of 2.6 and a price-to-earnings ratio of 41.2 based on trailing net income. Consensus analyst forecasts expect annual EPS of $3.03 for fiscal 2026, $2.98 for fiscal 2027, and $2.41 for fiscal 2028.
For broader context on how mature healthcare firms compare to tech leaders or high-growth small caps, check out our Apple stock forecast or our Rocket Lab stock forecast.
PFE stock forecast for the next 12 months
Wall Street analysts hold a cautious 12-month PFE outlook. According to Nasdaq consensus data, the average 12-month target price is $30.28, representing a 3.0% upside from today’s $29.39 price. Price targets range from a low of $25.00 to a high of $36.00.
Among 21 covering analysts, 6 issue buy ratings, 14 recommend holding the stock, and 1 issues a sell rating.
To reach the $36.00 high target over the next year, Pfizer needs sustained commercial adoption of its newer oncology products, cost-cutting executions, and stable sales for its primary care offerings. Conversely, falling toward the $25.00 low target would likely require regulatory delays, pricing pressures from health payers, or missing near-term earnings targets.
What is the PFE stock forecast for 2030?
To evaluate Pfizer’s multi-year path, we look at three long-term growth scenarios through 2030. The model starts with Pfizer’s trailing twelve-month revenue of $63.6 billion and applies varying annual growth rates, valuation multiples, and share count assumptions.
To support its current share price of $29.39 at a 2.6x price-to-sales ratio, Pfizer requires approximately $63.6 billion in 2030 revenue—essentially holding its current sales base flat.
| Scenario | Revenue growth per year | 2030 revenue | Price-to-sales | Shares | Implied share price |
|---|---|---|---|---|---|
| Bear | -1% | $61.1 billion | 2.1× | 5.93 billion | about $21.70 (-26%) |
| Base | 3% | $71.6 billion | 2.6× | 5.70 billion | about $33.08 (+13%) |
| Bull | 7% | $83.4 billion | 2.9× | 5.48 billion | about $44.12 (+50%) |

Bear case
In the bear case, Pfizer’s revenue contracts by about 1% annually, reducing total revenue to $61.1 billion by 2030. Patent expirations on major drugs outstrip new product launches, while competitive pressures squeeze profit margins. If the price-to-sales multiple drops to 2.1x and share dilution expands the float to 5.93 billion shares, the stock trades near $21.70, a 26% decline from current levels.
Base case
The base case assumes modest corporate growth of 3% per year, lifting annual revenue to $71.6 billion by 2030. Newly commercialized therapies and steady vaccine demand offset older drug revenue declines. Assuming the price-to-sales multiple remains stable at 2.6x and share repurchases gently lower the float to 5.70 billion shares, the share price rises to about $33.08, returning 13% upside.
Bull case
The bull case projects annual top-line growth of 7%, driving 2030 revenue to $83.4 billion. In this scenario, commercial breakthroughs in oncology and metabolic treatments deliver strong growth. With a expanding price-to-sales multiple of 2.9x and a reduced share count of 5.48 billion through active share buybacks, the stock reaches about $44.12, representing a 50% gain.
If you are interested in comparative long-term valuations across different sectors, read our Robinhood stock forecast or our MPLX stock forecast.
Risks to weigh
- Loss of Exclusivity: Patent expirations on key commercial drugs expose revenue to low-cost generic competition.
- Pipeline Execution: Clinical trial failures or FDA approval delays can erase expected future cash flows.
- Regulatory and Pricing Pressures: Government healthcare mandates and drug pricing restrictions could weigh on gross margins.
- Valuation Risks: A high trailing P/E ratio of 41.2 leaves the stock vulnerable if quarterly net income softs.
What to watch next
Key items to track include upcoming quarterly earnings reports and management’s update on full-year revenue guidance. Watch phase 3 clinical trial readouts across Pfizer’s oncology and rare disease programs, which determine pipeline commercialization potential. Pay attention to regulatory approval decisions from the FDA and European regulators, as well as capital allocation decisions regarding dividend payouts and share buyback programs.
FAQ
What is the PFE stock forecast for 2030?
Based on investing20 valuation scenarios, Pfizer stock could trade near $33.08 in a base case assuming 3% annual revenue growth and a 2.6x price-to-sales multiple. In a bull case with 7% yearly growth, shares could reach about $44.12, while a bear case with -1% annual decline points toward $21.70.
What is the 12-month average price target for Pfizer stock?
According to Nasdaq consensus data, Wall Street analysts set an average 12-month price target of $30.28 for Pfizer, ranging from a low of $25.00 to a high of $36.00. That average sits about 3.0% above the stock's $29.39 price as of November 6, 2026.
What are Wall Street analyst ratings for PFE?
Among 21 consensus analyst ratings tracking Pfizer, 6 rate the stock a buy, 14 recommend a hold, and 1 assigns a sell rating.
Market data: Nasdaq. Financials: Nasdaq. Scenario math: investing20.
This article is for information only and is not investment advice. Do your own research before investing.


